Using a retrospective cohort analysis, investigators at PHAR, LLC and Genentech, Inc. examined patterns of omalizumab use in the first 5 years after the drug’s approval. The study found that omalizumab is most often used with appropriate concomitant medications. In addition, most omalizumab prescriptions come from specialist physicians. These findings were published in the December 2011 edition of the Journal of Asthma.